WRC-CHINA 2018之展商推荐-DMG Deutsche Malaria GmbH
DMG Deutsche Malaria GmbH
Deutsche Malaria is based in Hamburg, the German partner city of Shanghai. It is a privately owned company financed by corporate and individual investors.
The company has commanded outstanding scientists, researchers and top medical institutions in Germany, SE Asia and Africa to develop a new and safe therapy against malaria. It is called fosmidomycin and is administered in combination with other antimalarials as a highly effective, well tolerated and safe treatment. It may also have a role in the initial treatment of severe malaria.
The artemisinin therapies first developed by Tu Youyou, Nobel Laureate of 2015, are becoming less effective due to resistant malaria parasites. This is a matter of considerable concern. As fosmidomycin is not cross-resistant with the artemisinin derivatives, it could play an important role in areas where artemisinin is losing its effectiveness.
Hence projects being pioneered by Deutsche Malaria maybe very well positioned for scientific and commercial cooperation with Chinese institutions and companies to bring new, powerful and safe solutions to fight malaria. Deutsche Malaria is very interested to join with partners to bring these projects to fruition. A number of these projects are aimed at fighting malaria in Africa and could be quickly implemented.
China has a high interest in the development of Africa as was shown on the Forum of China-Africa Cooperation at the beginning of September in Beijing, where President Xi Jinping announced US $ 60 billion in support for African countries.
Health is one of the most important issues to improve the quality of life. More than 200 million people fall ill with malaria each year. About 80% of the nearly 500,000 deaths each year are African children. This is very concerning and unacceptable but it can be changed. At the same time, new and effective therapies for travellers to Africa on business or as tourists are much needed.
Deutsche Malaria has solutions and is looking for dialogue and partnerships at the BIOTEC-CHINA 2018 conference.
Deutsche Malaria CEO Dr David BA Hutchinson has been invited as the keynote speaker in the conference and the speech title is Meeting the challenge of artemisinin resistance with fosmidomycin combination therapy. A novel approach with safety in children at the forefront
DMG Deutsche Malaria GmbH
Neuer Wall 72
20354 Hamburg
Germany
Voice +49-40-81 80 28
Cell +49-40-172 916 13 66
UK Office
Betsoms Farmhouse, Pilgrims Way
Westerham, Kent TN16 2DR
England
Dr David BA Hutchinson
Managing Director
david.hutchinson@deutschemalaria.com
Voice +44 - 1959 - 56 34 87
Fax +44 - 1959 - 56 29 31
DMG Deutsche Malaria GmbH
Deutsche Malaria总部位于德国上海友好城市汉堡市。它是一家由企业和个人投资者资助的私人公司。
该公司已聚集来自德国，东南亚和非洲的杰出科学家，研究人员和顶级医疗机构开发出一种新的安全的疟疾疗法。它被称为fosmidomycin，与其他抗疟药联合使用，是一种高效，耐药性良好且安全的治疗方法。它也可以在严重疟疾的初始治疗中发挥作用。
最初由2015年诺贝尔奖获得者屠呦呦开发的青蒿素疗法由于疟疾寄生虫的耐药性而变得不那么有效。这是一个值得关注的问题。由于fosmidomycin与青蒿素衍生物不具有交叉耐药性，因此它可能在青蒿素失去其有效性的地区发挥重要作用。
因此，由Deutsche Malaria开创的项目可能非常适合与中国机构和公司进行科学和商业合作，为抗击疟疾带来新的，强大的和安全的解决方案。Deutsche Malaria非常有兴趣与合作伙伴一起实现这些项目。其中一些项目旨在打击非洲的疟疾，并可迅速实施。
中国对非洲的发展有着浓厚的兴趣，正如9月初中非合作论坛在北京所展示的那样，习近平主席宣布向非洲国家提供600亿美元的支持。
健康是改善生活质量的最重要问题之一。每年有2亿多人患有疟疾。每年近500,000死亡人数中约有80％是非洲儿童。这是非常令人担忧和不可接受的，但这种现象可以改变。与此同时，非常需要为非洲商务旅行者或游客提供新的有效疗法。
Deutsche Malaria有良好的解决方案，并正在2018年会上寻求对话和合作。
Deutsche Malaria CEO Dr David BA Hutchinson 受邀出席BIOTEC-CHINA 2018年年会并做大会主旨报告，报告题目：用fosmidomycin联合疗法应对青蒿素抗药性的挑战。 一种治疗疟疾的并对儿童安全的全新疗法。
DMG Deutsche Malaria GmbH
Neuer Wall 72
20354 汉堡德国
Voice +49-40-81 80 28
Cell +49-40-172 916 13 66
英国办事处
Betsoms Farmhouse, Pilgrims Way
Westerham, Kent TN16 2DR
England
Dr David BA Hutchinson
总经理
david.hutchinson@deutschemalaria.com
Voice +44 - 1959 - 56 34 87
Fax +44 - 1959 - 56 29 31
WRC-CHINA 作为国内细胞治疗与再生医学领域专业的国际会议与展览会，将在全球范围内邀请参会代表、参展企业与专业观众，致力于为细胞治疗与再生医学领域搭建贸易与交流的国际性平台，为细胞治疗与再生医学领域产学研用不同单位在不同发展阶段寻找最合适的合作伙伴。
WRC-CHINA 2018 热诚欢迎您的参与！
联系我们：
2018 世界细胞治疗与再生医学大会暨展览会
WRC世界再生医学专家委员会
上海广贸会展服务有限公司
电话：86-13817254690
0086-21-80312776
邮箱：info@bonetec-china.com
官网：http://www.wrc-china.com/
